Literature DB >> 30877174

Imaging the Enzyme 11β-Hydroxysteroid Dehydrogenase Type 1 with PET: Evaluation of the Novel Radiotracer 11C-AS2471907 in Human Brain.

Jean-Dominique Gallezot1, Nabeel Nabulsi2, Shannan Henry2, Richard Pracitto2, Beata Planeta2, Jim Ropchan2, Shu-Fei Lin2, David Labaree2, Michael Kapinos2, Anupama Shirali2, Teresa Lara-Jaime2, Hong Gao2, David Matuskey2, Mark Walzer3, Gerard J Marek3, Susan Bellaire4, Nancy Yuan3, Richard E Carson2, Yiyun Huang2.   

Abstract

The 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme converts cortisone to cortisol and participates in the regulation of glucocorticoid levels in tissues. 11β-HSD1 is expressed in the liver, kidney, adipose tissue, placenta, and brain. 11β-HSD1 is a target for treatment of depression, anxiety, posttraumatic stress disorder, and also against age-related cognitive function and memory loss. In this study, we evaluated the radiotracer 11C-AS2471907 (3-(2-chlorophenyl)-4-(methyl-11 C)-5-[2-[2,4,6-trifluorophenoxy]propan-2-yl]-4H-1,2,4-triazole) to image 11β-HSD1 availability in the human brain with PET.
Methods: Fifteen subjects were included in the study. All subjects underwent one 2-h scan after a bolus administration of 11C-AS2471907. Two subjects underwent an additional scan after blockade with the selective and high-affinity 11β-HSD1 inhibitor ASP3662 to evaluate 11C-AS2471907 nondisplaceable distribution volume. Five subjects also underwent an additional scan to evaluate the within-day test-retest variability of 11C-AS2471907 volumes of distribution (V T).
Results: 11C-AS2471907 time-activity curves were best fitted by the 2-tissue-compartment (2TC) model. 11C-AS2471907 exhibited a regionally varying pattern of uptake throughout the brain. The V T of 11C-AS2471907 ranged from 3.7 ± 1.5 mL/cm3 in the caudate nucleus to 14.5 ± 5.3 mL/cm3 in the occipital cortex, with intermediate values in the amygdala, white matter, cingulum, insula, frontal cortex, putamen, temporal and parietal cortices, cerebellum, and thalamus (from lowest to highest V T). From the blocking scans, nondisplaceable distribution volume was determined to be 0.16 ± 0.04 mL/cm3 for 11C-AS2471907. Thus, nearly all uptake was specific and the binding potential ranged from 22 in the caudate to 90 in the occipital cortex. Test-retest variability of 2TC V T values was less than 10% in most large cortical regions (14% in parietal cortex) and ranged from 14% (cerebellum) to 51% (amygdala) in other regions. The intraclass correlation coefficient of 2TC V T values ranged from 0.55 in the white matter to 0.98 in the cerebellum.
Conclusion: 11C-AS2471907 has a high fraction of specific binding in vivo in humans and reasonable within-day reproducibility of binding parameters.
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  11β-hydroxysteroid dehydrogenase-1; brain; cortisol; positron emission tomography

Mesh:

Substances:

Year:  2019        PMID: 30877174     DOI: 10.2967/jnumed.118.219766

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  3 in total

1.  First in-human PET study and kinetic evaluation of [18F]AS2471907 for imaging 11β-hydroxysteroid dehydrogenase type 1.

Authors:  Shivani Bhatt; Nabeel B Nabulsi; Songye Li; Zhengxin Cai; David Matuskey; Jason Bini; Soheila Najafzadeh; Michael Kapinos; Jim R Ropchan; Richard E Carson; Kelly P Cosgrove; Yiyun Huang; Ansel T Hillmer
Journal:  J Cereb Blood Flow Metab       Date:  2019-03-21       Impact factor: 6.200

2.  Optimized Methodology for Reference Region and Image-Derived Input Function Kinetic Modeling in Preclinical PET.

Authors:  Jason Bini; Christine R Lattin; Takuya Toyonaga; Sjoerd J Finnema; Richard Carson
Journal:  IEEE Trans Radiat Plasma Med Sci       Date:  2021-06-11

3.  Challenges of Psychiatry Drug Development and the Role of Human Pharmacology Models in Early Development-A Drug Developer's Perspective.

Authors:  Tong Zhu
Journal:  Front Psychiatry       Date:  2021-01-27       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.